Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT05359432

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
  • Getz Pharma Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05359432
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05359432. Randomized; no masking; primary purpose treatment. Start 2020-07-01 (actual); primary completion 2021-08-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Vildagliptin
Lead sponsor
Getz Pharma (class: industry)

Record details

Record id
cardio:ct-nct05359432
Content hash
91874293e830f8c409577403e9c64bda904d885bd2ac10381a78c23cb581803f